Clinical Research Directory
Browse clinical research sites, groups, and studies.
ctDNA for Early Detection of Recurrence in Melanoma
Sponsor: Herlev and Gentofte Hospital
Summary
This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma. The hypothesis is that ctDNA can provide accurate detection of recurrence or metastasis, at the time of or earlier than current methods, leading to improved management and hopefully prognosis, based on earlier detection.
Official title: The Value of Circulating Tumour DNA in Early Detection of Recurrence of Melanoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
467
Start Date
2019-07-01
Completion Date
2028-01-01
Last Updated
2024-03-12
Healthy Volunteers
Not specified
Conditions
Locations (1)
Detp. of Pastic and Reconstructive Surgery, Herlev Hospital
Herlev, Denmark